Cargando…
Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
BACKGROUND: Although established therapies are effective in most patients with generalized myasthenia gravis (gMG), some patients do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted therapies for treatment-refractory gMG. OBJECTIVE: To d...
Autores principales: | Katyal, Nakul, Narula, Naureen, Govindarajan, Raghav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075396/ https://www.ncbi.nlm.nih.gov/pubmed/33325394 http://dx.doi.org/10.3233/JND-200584 |
Ejemplares similares
-
Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
por: Katyal, Nakul, et al.
Publicado: (2021) -
Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis
por: Johnson, Stephen, et al.
Publicado: (2021) -
Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series
por: Datta, Sorabh, et al.
Publicado: (2020) -
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
por: Vissing, John, et al.
Publicado: (2020) -
Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report
por: Digala, Lakshmi, et al.
Publicado: (2021)